The Qingdao-based maker of meals for particular medical functions is difficult worldwide corporations that also dominate the China market however might face tariff uncertainties
Key Takeaways:
- Sainte Dietary has filed for a Hong Kong IPO, boasting an inventory of heavyweight monetary backers and hovering income and income
- As Chinese language birthrates decline, the infant-focused maker of meals for particular medical functions is diversifying into China’s rising marketplace for aged diet
When Sainte Dietary Inc. made its first public disclosure for a deliberate Hong Kong IPO final Friday, it listed Citic Securities as its most important sponsor. However in an indicator of robust investor urge for food for this up-and-coming maker of toddler dietary merchandise, it revealed a short while later that CLSA would be part of the underwriting crew as general coordinator.
Sainte’s metrics are certainly spectacular for such an old-economy firm with greater than 20 years of historical past. Its income has nearly doubled during the last three years, rising from 491 million yuan ($68.3 million) in 2022 to 834 million yuan final 12 months. Income from cross-border e-commerce platforms amounted to 405.1 million yuan in 2024, making up 48.6% of its complete. The corporate’s adjusted internet revenue has additionally grown shortly, from 120.7 million yuan in 2022 to 199.4 million yuan in 2024. And its gross margin has hovered at an enviable degree of round 71% during the last three years.
Previously generally known as Shengtong Dietary Meals, Sainte was one among China’s earliest entrants within the home marketplace for meals for particular medical functions (FSMP), specializing primarily in specialty merchandise for infants with allergy symptoms, which accounted for 90% of its revenues in 2024.
The home market that also accounts for greater than half of Sainte’s gross sales is dominated by worldwide giants. Nestlé (NESN.SW) and Danone (BN.PA) are the nation’s largest and second-largest gamers, respectively, adopted by Sainte in third and Abbott Laboratories (ABT.US) in fourth. That makes Sainte first amongst its home friends, in accordance with third-party analysis within the itemizing doc. Just one different home firm is within the prime 5, dairy big China Feihe (6186.HK).
Feihe at present trades at a price-to-sales (P/S) ratio of two.32, that means Sainte might fetch a valuation of about 2 billion yuan if it may match that degree, based mostly on its 2024 gross sales. That would assist it to boost as a lot as 500 million yuan, if no more, giving it funds to scale up manufacturing at a brand new facility at present underneath development in Internal Mongolia.
The IPO marks simply the most recent fundraising for Sainte, which additionally raised 400 million yuan in a Sequence B spherical in February. It boasts an A-list of backers, together with SAIC Motor’s Hengxu Capital funding arm, Hillhouse Capital, Lee Kai-fu’s Sinovation Ventures and CICC.
FSMP merchandise require a doctor’s supervision and are dominated by merchandise for infants with particular wants. In China, the penetration charge for all FSMP merchandise is simply 3%, properly under the 40% charge in mature markets. In accordance with the itemizing doc, the Chinese language market is rising 18% yearly is predicted to succeed in 53.1 billion yuan by 2029, with toddler merchandise accounting for 27.4 billion yuan, or about half the overall.
The timing could also be good for firms like Sainte to problem their worldwide friends, who could possibly be hobbled by retaliatory tariffs from China if components of their provide chains are based mostly within the U.S. Sainte’s solely outdoors provider is in South Korea, making it comparatively immune from tariff wars that solely have an effect on items imported to China from the U.S. However that stated, it sells almost half its merchandise abroad, largely by e-commerce, although the itemizing doc would not specify how a lot, if any, goes to the U.S.
20 years of historical past
Sainte’s historical past goes again to 2005, when it was established because the FSMP division of Shengyuan Dietary, managed by the husband-and-wife crew Zhang Liang and Meng Xiuqing. Zhang based Synutra Worldwide in 1998 as an toddler system maker, and the corporate was listed on the Nasdaq from 2007 and 2017 earlier than Zhang took it non-public.
China had no home FSMP producers within the early 2000s, in accordance with the itemizing doc. As the present home chief within the area, Sainte now has 14 product segments and 7 licensed merchandise.
The robust investor curiosity in Sainte appears counterintuitive given China’s quickly declining delivery charge. 2024, a Yr of the Dragon on the Chinese language zodiac and favored by potential dad and mom, noticed an uptick in births to 9.5 million from 9 million in 2023, marking the best variety of annual births of any nation on this planet. Even so, the long-term outlook is bleak on account of components frequent to mature economies, together with later marriages and the excessive prices of elevating youngsters. Sainte counters that China’s Gen Z dad and mom are newly dedicated to creating positive their infants have correct diet and are fast to purchase specialty merchandise to deal with any perceived issues.
Nonetheless, Sainte realizes the demographic traits are working towards it and is diversifying into merchandise for adults to enhance its present portfolio. Demand for non-infant FSMP merchandise is predicted to growth as China’s inhabitants over the age of 60 rises, already accounting for greater than one-fifth of the inhabitants in 2023, based mostly on official sources. In accordance with Sainte’s prospectus, the marketplace for non-infant FSMP merchandise ought to develop by a median annual charge of 21.5% between 2024 and 2029, reaching 25.8 billion yuan in gross sales by 2029.
“Guided by our ethos of ‘Exact Diet, Skilled Care,’ we care in regards to the wants of particular teams, from infants grappling with allergy symptoms, lactose intolerance and preterm vulnerabilities to the silver tsunami of the growing older populace,” the corporate stated in its itemizing doc. Sainte’s 300-plus distributors promote by hospitals, postnatal care facilities, specialty shops and on-line, with over 17,000 factors of sale.
Sainte’s most important manufacturing facility within the Northeastern Chinese language metropolis of Qingdao, which it shared with its guardian Shengyuan Group till 2023, produced 1.7 tons of FSMP merchandise in 2024. It opened one other manufacturing unit in February this 12 months, and a 3rd is underneath development in Internal Mongolia, on account of open in 2026.
The corporate wants to maneuver shortly as a rising subject of home rivals nip at its heels. The annual variety of new FSMP registrations in China jumped from 13 in 2022 to 70 in 2023, and one other 42 registrations had been recorded final 12 months. Home corporations accounted for 174 out of 206 FSMP registrations in China as of Sept. 20, in accordance with the State Administration of Market Supervision, displaying native Chinese language firms need to attempt to acquire a bit of this main market.
That stated, the worldwide giants nonetheless have an enormous lead. Nestlé dominates with a 57% market share, adopted by Danone at 18.4%. Sainte is undoubtedly hoping to wrestle a few of that away for itself, and may gain advantage from nationalistic components as Chinese language develop more and more snug with home manufacturers. That would bode properly for its IPO if traders imagine it appears properly positioned to maintain up its robust development.
